phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Diagnostic Technology Advancements for Neuroendocrine Tumor Mapping Resulted in Dramatic Shifts in Access to Theranostics Care

A new study from the Harvey L. Neiman Health Policy Institute found that the introduction of PET-based Gallium-68 DOTATATE/DOTATOC radiotracers for imaging neuroendocrine tumors created substantial differences in patient access during its first four years of use. Compared with the older imaging agent, Indium-111 pentetreotide (Octreoscan(tm)), patients in small-rural areas traveled 134.9 additional miles on average to access Gallium-68 DOTATATE/DOTATOC. By comparison, patients in metropolitan-micropolitan areas traveled only 26.7 additional miles. The study, published in the Journal of the American College of Radiology, analyzed 3,365 claims for neuroendocrine tumor radiotracers.

April 30, 2026


April 30 2026

April 29 2026

April 28 2026

April 27 2026

April 26 2026

April 25 2026

April 24 2026

April 23 2026

April 22 2026

April 21 2026

April 20 2026

April 19 2026

April 18 2026

April 17 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy